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Abstract. One of the major problems in cancer therapies is the high occurrence of side effects 
intrinsic of anticancer drugs. Doxorrubicin is a conventional anticancer molecule used to treat a 
wide range of cancer, such as breast, ovarian and prostate. However, its use is associated with a 
number of side effects like multidrug resistance and cardiotoxicity. The association with 
nanomaterials has been considered in the past decade to overcome the high toxicity of these 
drugs. In this context, mesoporous silica nanoparticles are great candidates to be used as 
carriers once they are very biocompatible. Taking into account the combination of 
nanoparticles and doxorrubicin, we treated rats with chemically induced prostate cancer with 
systems based on mesoporous silica nanoparticles and a thermoreversible block copolymer 
(Pluronic F-127) containing doxorrubicin. Preliminary results show a possible improvement in 
tumor conditions proportional to the concentration of the nanoparticles, opening a perspective 
to use mesoporous silica nanoparticles as carrier for doxorrubicin in prostate cancer treatment. 
1.  Introduction  
It is known that one of the main problems related to cancer treatments is the high incidence of side 
effects caused by anticancer drugs. Doxorrubicin (DOX), for instance, is an antibiotic and anticancer 
that is commonly used to treat many types of cancers, such as breast, ovarian and prostate [1,2]. 
However, its efficacy is yet very limited for the occurrence of aggressive side effects, including 
mielosuppression, alopecia, multidrug resistance and cardiotoxicity [2,3].   
In the last years, many alternatives to minimize this issue have been studied. Among them, the 
association with nanoparticles is promissing. Their use as drug carriers is advantageous once they can 
provide a sustained release and increase the effectiveness of drug delivery [4,5]. Among 
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nanomaterials, mesoporous silica nanoparticles (MSNs) have a good perspective to be used as drug 
carriers because of their biocompatibility and safety profile [4]. These particles have high superficial 
area and great pore volume, which is very suitable to carry actives [4]. 
Another strategy to overcome the intrinsic toxicity of anticancer drugs is the association with 
materials that can provide a long-term release of the drug. This ensures a better drug distribution and 
avoids a premature degradation of the drug [6]. In this context, Pluronic F-127 (PF-127) is a 
biocompatible block copolymer, approved by the FDA, that has a transition sol-gel temperature near 
room temperature [7]. That is, it is liquid at low temperatures (e.g. refrigerator temperatures) and it 
gelates at room temperature, which makes it very suitable to reach in situ gelation [6].  
So, to obtain preliminary results about the antitumor potential of the association MSNs + DOX + 
PF-127 and the role of the nanoparticles in this process, we developed three systems containing these 
components and tested them in rats with chemically induced prostate cancer. The MSNs were used as 
carriers for DOX, to reach a sustained release of the drug. The polymer, in turn, was used as the matrix 
of the hydrogel, to achieve in situ gelation (i.e. inside the animal body after inoculation) and thus reach 
a prolonged release of the components.  
 
2.  Methods 
Synthesis and characterization of mesoporous silica nanoparticles (MSNs)  
MSNs were synthesized following the protocol developed by Paula et al. (2012) [8], which consists of 
a sol-gel synthesis based on the methods of Stöber [9] and Bein [10]. This approach allow to produce 
spherical and monodisperse nanoparticles with high colloidal stability in aqueous medium. In this 
context, 0.75 g of cetyltrimethylammonium bromide (CTAB) were added to a 0.050 mol L
-1
 
ammonium hydroxide solution of pH 11. Then, 3.2 mL of absolute ethanol were added and after 15 
minutes under magnetic stirring, 2.5 mL of tetraethyl orthosilicate (TEOS) were added. The reaction 
was maintained under reflux at 60C for two hours. After completing the reaction, a centrifugation 
step was carried out to separate the products (60 minutes at 18,400 rcf). To extract the CTAB, the 
products were resuspended in 90 mL of absolute ethanol and 10 mL of hydrochloric acid were added 
(1:9 HCL:Ethanol volume ratio), sonicating the mixture for 10 minutes. Finally, to obtain ethanolic 
suspensions of the nanoparticles, the mixture was centrifuged (60 minutes at 18,400 rcf) following two 
washing steps with absolute ethanol and resuspended in absolute ethanol.  
The size distribution and morphology of MSNs were analyzed by transmission electron microscopy 
(TEM) in the bright field mode (TEM-BF, Zeiss Libra 120, operating at 80 kV). Nitrogen-sorption 
assays were run to obtain information on nanoparticles surface area, pore volume and pore diameter 
(Accelerated Surface Area and Porosimetry System ASAP 2020 micromeritics). To calculate surface 
area and pore diameter, the BET (Brunauer-Emmet-Teller) and BJH (Barret-Hoyner-Halenda) 
methods were used, respectively, both using N2 adsorption branch. The pore volume was calculated 
from the single-point value adsorbed at P/P0 = ~0.94.   
 
Synthesis and characterization of hybrid systems 
To evaluate the antitumor potential of the hybrid systems as well as the role of MSNs in the 
association, we developed three systems. The only difference between them was the presence and 
concentration of the nanoparticles (Table 1). The systems were produced by firstly adding DOX to the 
copolymer solution in an ice bath under magnetic stirring and adding the nanoparticles lastly to avoid 
aggregation. The mixture was kept under these conditions overnight. All systems were produced in 
physiological saline solution (0.9% w/v NaCl) to keep the same osmotic pressure than the animals’ 
cells.  
The concentration of DOX was calculated based on Das et al. (2010) [2] to reach 1.5 mg of drug 
per kilogram of animal body weight, considering a dose application of 0.3 mL and an animal body 
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weight of 150 g (average). The PF-127 concentration was chosen regarding its gelation temperature 
(Tgel): Tgel had to fit within a temperature range that would allow easy manipulation of the systems, 
avoiding gelation inside the syringe and on the needles' walls and quickly gelation of the systems once 
applied inside the animals bodies, avoiding the diffusion of the systems to unwanted locations and 
premature release. So, the systems were characterized regarding their Tgel by adding 5 mL of the liquid 
mixture in a beacker in an ice bath with a thermometer. The mixture was heated in a constant rate and 
the temperature in which the bar stopped moving was considered the gelation temperature.  
In order to corroborate the potential for prolonged release of the systems, the release profile was 
studied in vitro through a membraneless dissolution method. To do so, 0.5 mL of ht hybrid systems 
were added to a weighed vial and incubated at 35C (which is the body temperature of mice used in 
the in vivo assays), using a dry bath, to reach thermal equilibrium. So, the vials were weighed and 0.5 
mL of the release medium (NaCl 0.9% w/v) were put carefully in order to avoid mixture. At pre-
determined intervals, the release medium was removed, the vial was weighed and a new release 
medium was put to avoid saturation. The dissolution rate was calculated in terms of weight loss 
against time.  
 
In vivo model 
To accomplish the in vivo study, seventeen 7-week-old male Fischer 344 rats were used and they were 
obtained from the Multidisciplinary Center for Biological Investigation (CEMIB) at University of 
Campinas (UNICAMP). The prostate cancer induction was performed in 13 animals and followed a 
new protocol based on Fávaro et al. (2014) [11] in which the animals are ready to be treated in 
approximately four months. Firstly, the animals received a daily subcutaneous injection of 100 mg kg
-1
 
testosterone cypionate diluted in 0.5 mL of peanut oil for three days. Then, the animals were 
anesthetized with 5 mg kg
-1
 of 2% xylazine hydrochloride and 60 mg kg
-1
 of 10% ketamyne 
hydrochloride in order to perform 0.5 cm suprapubic incision and inoculation of 0.2 mL of 15 mg kg
-1
 
of n-methyl-n-nitrosourea (MNU) dissolved in 0.3 mL of 1 M sodium citrate (pH 6.0) and 25% PF-
127, which allows in situ gelation of the solution. After one week, the animals received subcutaneous 
injections of 5 mg kg
-1 
testosterone cyprionate diluted in 5 mL of peanut oil on alternate days for 120 
days.  
Of the total number of animals, 4 animals comprised the healthy control group (Control, n=4, received 
no cancer induction) and 4 comprised the cancer group (Cancer, n=4, received no treatment), both 
groups received physiological saline (NaCl 0.9% w/v) for treatment. The rest of the animals were 
divided in 3 groups (n=3): Group S1 was treated with S1 system, Group S2 was treated with S2 
system and Group S3 was treated with S3 system. The treatment consisted of a weekly-dose of 
intraperitoneal inoculation of 0.3 mL of the respective treatment for 30 days. To prevent gelation 
inside the needles, the systems were kept in ice bath before each application. The animals received 
water and the same solid diet ad libitum (Nuvilab) and were allocadted in single solid-bottom boxes 
lined with wood shavings in a room with controlled light and temperature (12 hours light and 12 hours 
dark, 20-25C). The experimental protocol followed ethical principles in animal research. After 
treatment, the animals were euthanized and the occurrence of macroscopic changes were observed.  
 
3.  Results and Discussion 
 
Synthesis and characterization of MSNs  
Transmission electron microscopy images (Fig. 1a) show MSNs with spherical morphology and size 
distribution from 45 to 75 nm. Nitrogen-sorption experiments using BET and BJH methods revealed 








, with an average pore 
diameter of 4.8 nm. The nitrogen-sorption isotherm (Fig. 1b) shows an adsorption pattern that 
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resembles a type IV isotherm (IUPAC) with a subtle stepwise behavior around 0.4 P/P0, which is 
characteristic of well-ordered mesoporous materials [12].  
 
 
Figure 1. a) TEM images of MSNs with size distribution histogram (measuring at least 100 
nanoparticles) b) Nitrogen sorption isotherm of MSNs 
 
Synthesis and characterization of hybrid systems 
The hybrid systems were synthesized and firstly characterized regarding their Tgel (Table 1). All 
systems have a Tgel around 20C, which allows easy manipulation of them during dose applications 
and a rapid gelation inside the animal body (which temperature is around 35C).  
  
Table 1. Description of the hybrid systems. 




DOX (1.25 mg mL
-1
) 




DOX (1.25 mg mL
-1
) 








DOX (1.25 mg mL
-1
) 




22.0 ± 0.5 
 
 
 The achievement of long-term release was confirmed during the in vitro dissolution experiment 
(Fig. 2). Taking into account the concentration gradient induced by cells permanently on the hydrogel, 
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it is indeed expected that the hybrid system will delay the release of the components (DOX and MSNs, 
when it is the case) after the application.  
 
 
Figure 2. In vitro gel dissolution profiles of the systems. 
 
In vivo macroscopic analyses 
After treatment, the animals were euthanized and macroscopic changes were observed in order to get 
preliminary information on the antitumor potential of the systems (Table 2). 
 
 
Table 2.  Observed macroscopic changes of five experimental groups. 
Macroscopic observation Control Cancer S1 S2 S3 
No macroscopic changes 100% - 33,3% 100% 100% 
Cardiomegaly - - 66,6% - - 
Hernia - - 33,3% - - 
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Lesion in prostate base - 100% 33,3% - - 
 
 
The results from Table 2 show a decrease in frequency of lesions that is proportional to MSNs 
concentration. It might be a possible improvement in tumor conditions as the MSNs are added in the 
formulations, calling the attention for the role of the nanoparticles in this process. Also, we can a high 
frequency of cardiotoxic effects in group S1 (the one treated with the system with no nanoparticles), 
probably caused by intrinsic toxicity of DOX, although these effects can not be seen in groups treated 
with systems containing nanoparticles (S2 and S3). This is particularly interesting once it suggests that 
the MSNs might lead to a decrease in drug toxicity.   
It is known that nanoparticles are submitted to the enhanced permeability retention (EPR) effect, 
that allow macromolecules and particles up to 100 nm to accumulate in interstitial space of tumor cells 
[13]. This may increase the delivery of DOX. In turn, the prolonged and sustained release promoted by 
the hydrogel and the MSNs might protect the organisms from the intrinsic toxicity of the drug, 
increasing the efficacy of the treatment. 
 
4.  Conclusions 
 
After treating rats with chemically induced prostate cancer, preliminary macroscopic analyses showed 
a possible improvement in tumor conditions that was proportional to MSNs concentration and a 
possibly cardioprotection induced by the MSNs. The results suggest that the nanoparticles might play 
an important role in the treatment and that they have good perspectives to minimize the side effects of 
DOX. It might be occurring a combined effect from DOX and MSNs, caused by EPR effect along 
with sustained and prolonged release of the drug. This avoids premature degradation of DOX and 
enables its cell internalization, achieving a better drug distribution, increasing the efficacy of the drug 
and possibly decreasing its toxicity.  
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